Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxaliplatin clinical activity: a review.

J L Misset1, H Bleiberg, W Sutherland

  • 1Service des Maladies Sanguines Immunitaires et Tumorales, Hôpital Paul Brousse, Villejuif, France.

Critical Reviews in Oncology/Hematology
|August 11, 2000
PubMed
Summary

Oxaliplatin, a novel platinum-based chemotherapy, shows significant efficacy, especially in colorectal cancer (CRC) when combined with 5-FU. This agent demonstrates broad activity and a favorable safety profile across various cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.

Acta gastro-enterologica Belgica·2012
Same author

Differential diagnosis of adnexal masses: sequential use of the risk of malignancy index and HistoScanning, a novel computer-aided diagnostic tool.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2011
Same author

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.

British journal of cancer·2010
Same author

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

British journal of cancer·2008

Area of Science:

  • Medical oncology
  • Pharmacology
  • Cancer research

Background:

  • Oxaliplatin is a third-generation platinum compound with a 1,2-diaminocyclohexane (DACH) ligand.
  • It exhibits preclinical and clinical activity in diverse tumor types.

Purpose of the Study:

  • To evaluate the efficacy and safety of oxaliplatin in various cancers.
  • To explore its synergistic effects with other chemotherapeutic agents.

Main Methods:

  • Phase III trials in colorectal cancer (CRC).
  • Combination therapy studies with 5-FU, CPT-11, and Raltitrexed.
  • Clinical investigations in advanced ovarian cancer (AOC), breast, lung, prostate, and other cancers.

Main Results:

Related Experiment Videos

  • Oxaliplatin demonstrates synergy with 5-FU in CRC, including 5-FU-resistant and previously untreated cases.
  • It shows efficacy as a single agent and in combination therapies for advanced ovarian cancer.
  • Lack of cross-resistance with other platinum agents (cisplatin, carboplatin) is noted.

    • Conclusions:

    • Oxaliplatin is an important new anticancer agent with a favorable safety profile.
    • Its role in medical oncology is expanding, with ongoing investigations in multiple cancer types.